#	Pagina
attuale pagina	/open-h2020/projects/222549/index.html

Opendata, web and dolomites

PD-MIND SIGNED

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Total Cost €

EC-Contrib. €

Partnership

Views

PD-MIND project word cloud

Explore the words cloud of the PD-MIND project. It provides you a very rough idea of what is the project "PD-MIND" about.

put data trials marker imaging randomized agonist stakeholders outcomes treat suggested primary world motor outcome area effort considerably cognitive csf pd selective symptoms ample positioned multicentre nicotinic biomarker people biomarkers partnership alzheimer mci predictors impairment mild neurodegenerative blood complement composite parkinson engaged efpia patient perspectives trial integration hence receptors members diagnosed start experts azd0328 astrazeneca sustain clinical disease execute cross mind public patients cognition score alpha secondary index intensity unmet epidemiological international receptor cogtracktm consist involvement subsequent placebo disseminate

Project "PD-MIND" data sheet

The following table provides information about the project.

Coordinator	KING'S COLLEGE LONDON Organization address address: STRAND city: LONDON postcode: WC2R 2LS website: www.kcl.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	2˙131˙609 €
EC max contribution	999˙698 € (47%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2017-13-two-stage
Funding Scheme	IMI2-RIA
Starting year	2019
Duration (year-month-day)	from 2019-05-01 to 2022-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KING'S COLLEGE LONDON KING'S COLLEGE LONDON Organization address address: STRAND city: LONDON postcode: WC2R 2LS website: www.kcl.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	coordinator	524˙820.00
2	THE UNIVERSITY OF EXETER THE UNIVERSITY OF EXETER Organization address address: THE QUEEN'S DRIVE NORTHCOTE HOUSE city: EXETER postcode: EX4 4QJ website: www.ex.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (EXETER)	participant	184˙398.00
3	STICHTING LYGATURE STICHTING LYGATURE Organization address address: JAARBEURSPLEIN 6 city: UTRECHT postcode: 3521 AL website: http://www.lygature.org/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	100˙937.00
4	TECHNISCHE UNIVERSITAET DRESDEN TECHNISCHE UNIVERSITAET DRESDEN Organization address address: HELMHOLTZSTRASSE 10 city: DRESDEN postcode: 1069 website: http://www.tu-dresden.de/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (DRESDEN)	participant	58˙125.00
5	UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA Organization address address: Via dei Vestini 31 city: CHIETI postcode: 66013 website: www.unich.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (CHIETI)	participant	58˙125.00
6	Masarykova univerzita Masarykova univerzita Organization address address: Zerotinovo namesti 9 city: BRNO STRED postcode: 60177 website: http://www.muni.cz contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CZ (BRNO STRED)	participant	40˙625.00
7	HELSE STAVANGER HF HELSE STAVANGER HF Organization address address: GERD RAGNA BLOCH THORSENS GATE 8 city: STAVANGER postcode: 4011 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (STAVANGER)	participant	16˙417.00
8	NORGES PARKINSONFORBUND NORGES PARKINSONFORBUND Organization address address: KARL JOHANS GATE 7 city: OSLO postcode: 154 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (OSLO)	participant	16˙250.00
9	ASTRAZENECA AB ASTRAZENECA AB Organization address address: Vastra Maelarhamnen city: SODERTAELJE postcode: 151 85 website: www.astrazeneca.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (SODERTAELJE)	participant	0.00
10	PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG Organization address address: VAUXHALL BRIDGE RAOD 215 city: LONDON postcode: SW1V 1EJ website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	0.00

Map

Project objective

Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). There is ample evidence from epidemiological studies as well as (pre)clinical research that Nicotinic receptors are involved in PD and cognition. Recently a clinical trial suggested that selective α7 nicotinic receptor agonist improved cognition in PD patients, as a secondary outcome measure. Hence, the main goal of PD-MIND is to show the potential of the Astrazeneca nicotinic α7 agonist AZD0328 in a randomized, placebo-controlled, international multicentre, cross-over study on cognition in people diagnosed with PD-MCI. We will assess the Attention Intensity Index composite score from the CogTrackTM system as primary outcome measure and other clinical aspects (cognition, motor symptoms) as secondary outcomes. In addition, blood, CSF and imaging biomarkers will be assessed as potential predictors of response, and as marker of target involvement. Patients (Public and Patient Involvement) and other stakeholders will be engaged from the start to allow integration of end-user perspectives in the design and execution of the project. PD-MIND will put considerably effort to disseminate and exploit clinical outcome data and biomarker results, and to sustain the partnership for subsequent phase 3 clinical studies. PD-MIND consortium consist of world-leading PD-MCI experts in the area of clinical trials, clinical coordination, project management, data management and analysis, and biomarkers. As such the consortium is well positioned to execute the proposed work and complement the EFPIA members.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PD-MIND" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PD-MIND" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors